Barclays Sees Bayer at €60 After Supreme Court Win, but Anti-Dumping Tariffs on China Add a New Twist
Published on 07/14/2026 at 11:56 | Redaktion boerse-global.de
Bayer’s stock has more than doubled from a 52-week low of €25.09 recorded in early August 2025, a surge driven by an extraordinary series of legal, financial, and commercial catalysts. The latest push comes from the U.S. Supreme Court, where a decisive 7–2 ruling in Monsanto Co. v. Durnell has dismantled a key legal avenue used by thousands of plaintiffs claiming that Roundup’s label lacked a cancer warning. The decision, handed down in late June, held that the federal pesticide law FIFRA preempts state-law failure-to-warn claims requiring labels beyond those approved by the EPA. The original award of $1.25 million to the plaintiff Durnell was vacated, and the precedent is expected to sharply limit future Roundup litigation.
Beyond the courtroom, Bayer has been busy shoring up its balance sheet and protecting its glyphosate franchise. In February, the company struck a settlement agreement worth up to $7.25 billion to resolve approximately 60,000 existing claims over a 21-year period. A fairness hearing on that deal is scheduled for 19 August, a date now widely viewed as the next major inflection point for the stock. Adding to the financial cushion, private-equity giant Apollo is injecting €3 billion into a spin-out of Bayer’s long-acting reversible contraceptive (LARC) business, leaving the pharmaceutical group as majority shareholder while freeing up capital for debt reduction or further investments.
On the trade front, Bayer is going on the offensive against Chinese competition. Early July saw the group file for anti-dumping tariffs on Chinese-origin glyphosate and establish a new U.S.-based entity, Ruveon LLC, to handle the active ingredient’s American business. The move follows a sharp 24% jump in the TC price of Chinese glyphosate between March and April, a shift that has altered the global pricing landscape. Together, the tariff petition and the new corporate structure signal Bayer’s intent to shield its agrochemical margins from cheap imports while consolidating its market position.
Should investors sell immediately? Or is it worth buying Bayer?
Analyst sentiment has turned increasingly bullish, though with notable caveats. Barclays lifted its price target by €10 to €60, reiterating an “Overweight” rating, citing both the Supreme Court victory and the Apollo deal as reasons for reduced risk. UBS also kept a “Buy” recommendation, albeit with a more modest target of €52, reflecting what analyst Matthew Weston sees as limited upside from current levels. Not all houses share the enthusiasm: Jefferies has maintained a more cautious stance, pointing to Bayer’s still-heavy debt load and the fact that the stock has already rallied substantially in recent weeks.
The technical picture reflects that rally’s intensity. At €49.79, shares trade 22.49% above their 50-day moving average of €40.65 and 31.37% above the 200-day line of €37.90. The relative strength index sits at 68.0—elevated but not yet in overbought territory. With 30-day annualized volatility running at 60.54%, the ride remains choppy. The 52-week high of €53.86, set on 3 July, is now just 7.6% above the current price, while the gap to the 12-month low of €25.09 stands at 98.41%. Market capitalisation has swelled to €49.24 billion.
For the near term, Bayer has entered its quiet period ahead of half-year results expected in early August, limiting corporate commentary. That leaves the 19 August fairness hearing as the single most consequential event on the horizon. If the settlement wins final approval, the legal overhang that has depressed the shares for years could finally lift—but the elevated volatility and the split among analysts suggest that the market remains far from unanimous on the path ahead.
Ad
Bayer Stock: New Analysis - 14 July
Fresh Bayer information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
